Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Prove my point. LOL
Goodbye
And Les has been saying for years that BP is interested
What you just said is very slanderous
Is it possible that Merck want to begin a series of trials against 13+ types of cancer immediately.
And Dr Duffy enters the door
Interesting.
If Linda wanted to create a powerhouse pharmaceutical company why sell the production side? This should be a profit center.
What length of time does northwest have a production contract with cognate???
If I was BP I would want all profit centers in house. Licensing, production patents distribution etc all in house
Could a deal been made two years ago?? Contingent on results??
Why did Linda sell cognate back to management?
Things to ponder
Is it possible that northwest has been working with Merck for quite a while??
No, actually competing against Keytruda optivo and the head microwave
Meanwhile the tail gets longer
Shall we ask Willie Nelson to do a fundraiser for you???
That poster on yahoo is a daily clown. Disregard
Agree 100%
Dr Duffy:
Dr. Duffy is joining NW Bio from Merck, where he has served as Research Scientific Director in the Keytruda® (pembrolizumab) program during the last five years. Dr. Duffy’s roles included scientific support and outreach to health care providers and national and regional scientific leaders in over 20 different solid tumors and hematologic malignancies (blood cancers and lymphomas) relating to Merck’s clinical development and commercialization of Keytruda, as well as ongoing scientific support for Merck’s Investigator-Initiated Study Program. He served as the national contact point between the scientific affairs team working with medical professionals in the field and the internal research and development team in Merck for the Keynote-024 study in first-line non-small cell lung cancer, the Keynote-522 and -756 studies in triple negative breast cancer and ER+/HER2- breast cancer, and the Keynote-641 study in metastatic prostate cancer.
Dr. Duffy also served as Scientific Affairs Strategy and Training Lead in Merck’s Global Center for Scientific Affairs for Merck’s immuno-oncology franchise for hematologic malignancies. Dr. Duffy was the recipient of numerous achievement awards during his tenure at Merck.
In his roles at Merck, Dr. Duffy has been involved in the Keytruda development program from its early days through its wide commercialization. He has gained extensive experience with clinical trial designs and strategies, clinical results and feedback from medical professionals. He has built a nationwide network with key opinion leaders in both the clinical and the scientific arenas.
Only dilution going on right now is Linda adding some cream to her coffee
I agree 100%!!!
You will know it if a big trade passes by
Collecting shares
Hummmmmm. Very interesting.
Thanks!
More like sour grapes at this point
How many still alive after all these YEARS????
Looks like the mm’s were accumulating for someone
And happens to be at the Glio Drug Development Summit
At 20.00 per share
Ice cold suds!
Steak!!
Victory tour??
Excellent!
He is still in line.